Home|Journals|Articles by Year|Audio Abstracts
 

Original Article

J App Pharm Sci. 2021; 11(1): 121-128


Synthesis of 2-styrylchromones: In vitro and in silico anticancer activity evaluation

Brilliana Via Safitri, Alfinda Novi Kristanti, Hery Suwito, Kautsar Ul Haq, Dicky Hendriyanto.




Abstract
Cited by 2 Articles

The efforts to obtain cancer drugs are still a topic of many research studies considering that cancer is one of the main causes of human death. 2-Styrylchromones are a group of compounds with potential anticancer activity. This research was conducted to synthesize some 2-styrylchromones which involved the formation of 2-methylchromone, followed by aldol condensation with various benzaldehydes. The compound structures were determined using spectroscopic methods, which included ultra violet-visible, Fourier-transform infrared, proton nuclear magnetic resonance, carbon nuclear magnetic resonance- attached proton test APT, and high-resolution mass spectrometry. The toxicity test of the synthesized compounds was carried out in vitro against Henrietta Lacks cancer cells and in silico by molecular docking of the human kinesin Eg5 receptor. The results showed that the synthesized compound substituted with three methoxy groups presented the best anticancer activity, both in vitro (inhibition 100%) and in silico tests (grid score −41,029 kcal/mol).

Key words: 2-styrylchromone, aldol condensation, molecular docking, MTT assay, HeLa cell, human kinesin Eg5






Full-text options


Share this Article


Online Article Submission
• ejmanager.com




ejPort - eJManager.com
Refer & Earn
JournalList
About BiblioMed
License Information
Terms & Conditions
Privacy Policy
Contact Us

The articles in Bibliomed are open access articles licensed under Creative Commons Attribution 4.0 International License (CC BY), which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.